Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene ...

Transformative breakthrough in pediatric leukemia made possible by decades ... rates for children with standard-risk (SR) ALL. The results are so impactful that the COG has suspended all ongoing ...

We conducted a phase 1b–2 multicenter study of obe-cel in adults (≥18 years of age) with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). The main cohort, cohort 2A ...

Aucatzyl is a chimeric antigen receptor (CAR) T-cell therapy, a type of therapy that uses genetic modification to train the ...

2024 — Scientists have identified novel genetic variations that influence relapse risk in children with standard risk B-cell acute lymphoblastic leukemia (SR B-ALL), the most common childhood ...

The maintenance treatment phase for childhood acute lymphoblastic leukaemia (ALL) usually takes 2 years from the start of consolidation 1 treatment. Maintenance means your child has a more gentle ...

resulted in durable remissions among patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), according to results from the phase Ib/II FELIX trial. In a cohort of 94 ...